Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Titel:
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Auteur:
Saad, Fred Clarke, Noel W Oya, Mototsugu Shore, Neal Procopio, Giuseppe Guedes, João Daniel Arslan, Cagatay Mehra, Niven Parnis, Francis Brown, Emma Schlürmann, Friederike Joung, Jae Young Sugimoto, Mikio Sartor, Oliver Liu, Yu-Zhen Poehlein, Christian Barker, Laura del Rosario, Paula Michelle Armstrong, Andrew J